Viewing Study NCT01933932

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:55 PM
Ignite Modification Date: 2026-06-27 @ 2:49 AM
Study NCT ID: NCT01933932
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-19
First Post: 2013-08-29
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage … View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Mitogen-Activated Protein Kinase Kinase inhibitor; Non Small Cell Lung Cancer; … View